- Annovis Bio Provides Corporate Updates and Reports Fourth Quarter and Full Year 2023 Financial Results
- Annovis Announces Publication That Supports Understanding of Buntanetap’s Mechanism of Action in Humans
- Annovis Bio Provides Data Announcement Update for the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces Participation in Forum Discussion at AD/PD™ 2024
- Annovis Bio Announces Last Patient Last Visit in the Phase II/III Study of Buntanetap in Alzheimer’s Disease
- Annovis Bio Announces the Filing of New Patent Application for Treatment of Mental Illnesses Expanding the Company’s Portfolio
- Annovis Bio Refines Timeline for Parkinson’s Phase III Study Data Announcement
- Annovis Bio to Participate in the 139th Yale CEO Summit
- Annovis Bio Announces Last Patient Last Visit in the Phase III Study of Buntanetap in Parkinson’s Disease
- Annovis Bio Appoints Andrew Walsh as Vice President Finance
More ▼
Key statistics
On Thursday, Annovis Bio Inc (ANVS:NYQ) closed at 9.85, 81.73% above the 52 week low of 5.42 set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.11 |
---|---|
High | 9.88 |
Low | 9.04 |
Bid | 9.74 |
Offer | 10.20 |
Previous close | 9.85 |
Average volume | 174.87k |
---|---|
Shares outstanding | 11.01m |
Free float | 8.30m |
P/E (TTM) | -- |
Market cap | 98.99m USD |
EPS (TTM) | -6.12 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:10 BST.
More ▼